Experimental drug cocktail targets tough childhood cancers in adults

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed Ewing's sarcoma * Ewing's sarcoma must have progressed following at least one standard prior chemotherapy regimen * Life expectancy of at least 16 weeks * Willing to comply with the protocol for the duration of the study including pre- and post-treatment biopsies, undergoing treatment, scheduled visits and examinations including follow up * Presence of measurable disease * Prior approval from insurance company to obtain oral temozolomide for the duration of the study Exclusion Criteria: * Involvement in the planning and/or conduct of the study * Previous enrollment in the present study * Participation in another clinical study with an investigational product during the 21 days prior to first dose of olaparib and temozolomide * Receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment * Concurrent use of the following classes of inhibitors of CYP3A4: azole antifungals, macrolide antibiotics, protease inhibitors * Persistent clinically significant toxicities caused by previous cancer therapy * Previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia * Symptomatic uncontrolled brain metastases * Major surgery within 14 days of starting study treatment * Considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection * Unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of study medication * Pregnant or breastfeeding * Known to be serologically positive for HIV and receiving antiviral therapy * Subjects with known active hepatitis B or C * Known hypersensitivity to olaparib or any of the excipients of the product * Uncontrolled seizures * Need to continue treatment with any prohibited medications or have not completed the appropriate washout period for a prohibited medication